- Aveo Oncology (NASDAQ:AVEO) and Japanese partner Astellas Pharma (OTCPK:ALPMF) plan to end a Phase II study of the Tivozanib drug for treating breast cancer after not being able to enroll enough patients in the trial.
- The latest blow to Aveo comes after the FDA rejected Tivozanib as a treatment for kidney cancer in June, due to inconsistent study results. (PR)